ATH to present at MST Rare Diseases Rich Returns Forum
Released
Released
Announcement PDF
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns
Forum on 22 June 2023
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 21 June 2023: Alterity Therapeutics
(ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated
to developing disease modifying treatments for neurodegenerative diseases, today announced
that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and
participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on
Thursday, 22 June 2023 at 10:30 a.m. AEST (Wednesday, 21 June 2023 at 5:30 p.m. Pacific Time).
A link to the live webinar may be accessed on the Alterity website under the Investors section
Events and Presentations.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has
the potential to treat various Parkinsonian disorders and is currently being evaluated in two
Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery
platform generating patentable chemical compounds to treat the underlying pathology of
neurological diseases. The Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s web site at
www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Share your feedback
Discover